ING Groep NV Increases Stock Holdings in Gilead Sciences, Inc. $GILD

ING Groep NV raised its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 95.1% during the 4th quarter, HoldingsChannel reports. The firm owned 364,354 shares of the biopharmaceutical company’s stock after acquiring an additional 177,642 shares during the period. ING Groep NV’s holdings in Gilead Sciences were worth $44,721,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Vermillion Wealth Management Inc. grew its stake in shares of Gilead Sciences by 623.0% in the 4th quarter. Vermillion Wealth Management Inc. now owns 723 shares of the biopharmaceutical company’s stock valued at $89,000 after purchasing an additional 623 shares during the last quarter. Valtrion Capital Management LLC purchased a new position in shares of Gilead Sciences in the 4th quarter valued at approximately $300,000. DB&C Advisors LLC acquired a new stake in shares of Gilead Sciences in the 4th quarter valued at approximately $1,569,000. Cookson Peirce & Co. Inc. lifted its holdings in shares of Gilead Sciences by 12.2% in the 4th quarter. Cookson Peirce & Co. Inc. now owns 11,275 shares of the biopharmaceutical company’s stock valued at $1,384,000 after buying an additional 1,230 shares during the period. Finally, XML Financial LLC acquired a new stake in shares of Gilead Sciences in the 4th quarter valued at approximately $251,000. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Citi and Scotiabank both reiterated bullish views on Gilead, with each firm maintaining a Buy rating, which can support investor confidence in the stock. Gilead Sciences (GILD) Receives a Buy from Citi
• Positive Sentiment: Gilead highlighted progress on lenacapavir in South Africa, where the government and Global Fund are accelerating access to the HIV prevention drug, reinforcing the company’s growth story in HIV. Gilead Applauds Collaborative Efforts to Launch Lenacapavir for HIV Prevention in South Africa
• Positive Sentiment: Gilead and Lakefront completed the acquisition of Ouro Medicines, expanding the inflammation/autoimmune pipeline around gamgertamig, a potential first-in-class T cell engager. Gilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline
• Positive Sentiment: Gilead’s inclusion in a list of “best quality growth stocks” may add to the market’s view that the company remains a high-quality large-cap healthcare name. 5 Best Quality Growth Stocks to Buy
• Neutral Sentiment: Industry-wide biopharma M&A remains active, and Gilead was mentioned among the sector’s deal-making leaders, which keeps takeover speculation and pipeline deal optionality in focus. Gilead, Merck, Eli Lilly Lead $106 Billion Biopharma Takeover Wave In 2026
• Neutral Sentiment: Gilead also reported a clinical milestone in its IDEAL PBC trial, which could become a future catalyst if the study continues to progress positively. Gilead’s IDEAL PBC Trial Reaches Key Milestone, Setting Up a New Liver Disease Catalyst

Wall Street Analyst Weigh In

Several research firms have recently commented on GILD. Truist Financial reissued a “buy” rating and issued a $157.00 price target (up from $155.00) on shares of Gilead Sciences in a report on Friday, May 8th. JPMorgan Chase & Co. raised their price target on Gilead Sciences from $150.00 to $160.00 and gave the company an “overweight” rating in a report on Wednesday, February 11th. Royal Bank Of Canada reissued an “overweight” rating and issued a $122.00 price target on shares of Gilead Sciences in a report on Monday, June 1st. Wolfe Research raised their price target on Gilead Sciences from $155.00 to $170.00 and gave the company an “outperform” rating in a report on Thursday, February 12th. Finally, Scotiabank raised their price target on Gilead Sciences from $140.00 to $177.00 and gave the company a “sector outperform” rating in a report on Wednesday, February 11th. Twenty-six equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $156.93.

Gilead Sciences Stock Performance

NASDAQ GILD opened at $129.16 on Friday. Gilead Sciences, Inc. has a 1-year low of $104.46 and a 1-year high of $157.29. The company has a market capitalization of $160.36 billion, a P/E ratio of 17.60 and a beta of 0.31. The business has a 50 day moving average price of $134.38 and a 200 day moving average price of $134.31. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.97 and a quick ratio of 1.77.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share for the quarter, beating the consensus estimate of $1.91 by $0.12. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.The firm had revenue of $6.96 billion during the quarter, compared to the consensus estimate of $6.91 billion. During the same period last year, the business posted $1.81 EPS. Gilead Sciences’s quarterly revenue was up 4.4% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. Sell-side analysts expect that Gilead Sciences, Inc. will post -0.79 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, June 29th. Investors of record on Monday, June 15th will be paid a $0.82 dividend. This represents a $3.28 annualized dividend and a yield of 2.5%. The ex-dividend date of this dividend is Monday, June 15th. Gilead Sciences’s dividend payout ratio (DPR) is presently 44.69%.

Insider Activity at Gilead Sciences

In related news, insider Johanna Mercier sold 28,000 shares of the firm’s stock in a transaction that occurred on Friday, May 15th. The stock was sold at an average price of $131.29, for a total value of $3,676,120.00. Following the completion of the transaction, the insider directly owned 125,779 shares of the company’s stock, valued at $16,513,524.91. This trade represents a 18.21% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the firm’s stock in a transaction that occurred on Friday, May 15th. The shares were sold at an average price of $132.27, for a total value of $396,810.00. Following the completion of the transaction, the chief financial officer directly owned 173,191 shares of the company’s stock, valued at $22,907,973.57. The trade was a 1.70% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 68,000 shares of company stock valued at $9,047,570 in the last ninety days. Corporate insiders own 0.30% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.